July 10, 2019 / 6:36 AM / a year ago

GSK's Dovato meets primary goal in late-stage HIV study

July 10 (Reuters) - British Drugmaker GlaxoSmithKline Plc on Wednesday said its two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients for 48 weeks at similar levels as the patients’ previous three-drug treatment.

The company’s HIV drugs division ViiV said the late stage study evaluated the effectiveness of Dovato, a combination of dolutegravir and lamivudine, in adults who switched to the regimen from at least a triple combination TAF-containing treatment.

Pfizer Inc and Shionogi & Co Ltd have small stakes in ViiV. (Reporting by Pushkala Aripaka in Bengaluru; Editing by Bernard Orr)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below